



Ohmx Corporation



Contact:
Charles Pennington

Location:
Evanston, IL

Email:
Charles.P@Ohmx.com

Tel:
847-491-8508

Website:
www.ohmx.com



Company Profile

Industry Sector: Medical Diagnostics

Company Overview: Based in Evanston, IL, Ohmx is a clinical diagnostics company developing an accurate, reliable, low-cost, and comprehensive system that quantifies analytes from low-volume biological samples. In addition to developing point-of-care tests (POCT), Ohmx is believed to be developing the only comprehensive platform that can provide analyses of proteins and small molecules at the POC. Ohmx intends to bring to market a large menu of POC tests for screening, monitoring and detection of both acute and chronic diseases.

Target Market(s): Major Hospitals and Reference Labs



Key Value Drivers

Technology*: Proteolytic activity assay for Prostate Specific Antigen

Competitive Advantage:

Determine the aggressiveness/recurrence of prostate cancer

- Non-invasive sample collection
- No sample prep required
- Single target
- Simple data analysis
- Fast (mix and read with a plate reader)

Plan & Strategy:

Develop a microplate based assay and demonstrate performance characteristics to attract the attention of development partners



Management

Leadership:

Charles Pennington, CEO
Dr. Fang Lai, VP of R&D
Dr. Paul Bao, VP of Product Development
Jorge Castanos, VP of Regulatory and Compliance

Scientific Advisory Board:

Harry B. Gray, Ph.D., California Institute of Technology.
Gary F. Blackburn, Ph.D. Chief Executive Officer of Claremont BioSolutions
Thomas O'Halloran, Ph.D., Northwestern University.
Holden Thorp, Ph.D., Provost at Washington University in St. Louis
Richard P. Van Duyne, Ph.D., Northwestern University.



Product Pipeline

1. PPA Test 1 for non-aggressiveness of prostate cancer
2. PPA Test 2 for biochemical recurrence of prostate cancer 2-3 years post surgery



Small Business Innovation Research (SBIR)
Small Business Technology Transfer (STTR)

National Institutes of Health
Commercialization Assistance Program (NIH CAP)

